share_log

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $231

Benzinga ·  Oct 31 20:51  · Ratings

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $218 to $231.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment